Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2023

Open Access 01-12-2023 | Alzheimer's Disease | Review

Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease

Authors: Drew A. Gillett, Rebecca L. Wallings, Oihane Uriarte Huarte, Malú Gámez Tansey

Published in: Journal of Neuroinflammation | Issue 1/2023

Login to get access

Abstract

Background

Alterations in progranulin (PGRN) expression are associated with multiple neurodegenerative diseases (NDs), including frontotemporal dementia (FTD), Alzheimer’s disease (AD), Parkinson’s disease (PD), and lysosomal storage disorders (LSDs). Recently, the loss of PGRN was shown to result in endo-lysosomal system dysfunction and an age-dependent increase in the expression of another protein associated with NDs, glycoprotein non-metastatic B (GPNMB).

Main body

It is unclear what role GPNMB plays in the context of PGRN insufficiency and how they interact and contribute to the development or progression of NDs. This review focuses on the interplay between these two critical proteins within the context of endo-lysosomal health, immune function, and inflammation in their contribution to NDs.

Short conclusion

PGRN and GPNMB are interrelated proteins that regulate disease-relevant processes and may have value as therapeutic targets to delay disease progression or extend therapeutic windows.
Literature
1.
Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinson’s Dis. 2018;8(s1):S3-8.CrossRef
2.
Logroscino G, Piccininni M, Marin B, Nichols E, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(12):1083–97.CrossRef
3.
Matthews KA, Xu W, Gaglioti AH, Holt JB, Croft JB, Mack D, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimer’s & Dementia. 2019;15(1):17–24.CrossRef
4.
Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106.CrossRef
5.
Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. npj Parkinson’s Dis. 2020;6(1).
6.
Nalls MA, Blauwendraat C, Sargent L, Vitale D, Leonard H, Iwaki H, et al. Evidence for GRN connecting multiple neurodegenerative diseases. Brain Commun. 2021;3(2).
7.
Brouwers N, Nuytemans K, Julie Z, Gijselinck I, Engelborghs S, Theuns J, et al. Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol. 2007;64(10):1436–46.PubMedCrossRef
8.
Brouwers N, Sleegers K, Engelborghs S, Maurer-Stroh S, Gijselinck I, van der Zee J, et al. Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology. 2008;71(9):656–64.PubMedCrossRef
9.
Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, Marcone A, et al. Novel exon 1 progranulin gene variant in Alzheimer’s disease. Eur J Neurol. 2008;15(10):1111–7.PubMedCrossRef
10.
Fenoglio C, Galimberti D, Cortini F, Kauwe JSK, Cruchaga C, Venturelli E, et al. Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer’s disease. J Alzheimer’s Dis. 2009;18(3):603–12.CrossRef
11.
Kämäläinen A, Viswanathan J, Natunen T, Helisalmi S, Kauppinen T, Pikkarainen M, et al. GRN variant rs5848 reduces plasma and brain levels of granulin in Alzheimer’s disease patients. J Alzheimer’s Dis. 2012;33(1):23–7.CrossRef
12.
Lee MJ, Chen TF, Cheng TH, Chiu MJ. rs5848 variant of progranulin gene is a risk of Alzheimer’s disease in the Taiwanese population. Neurodegener Dis. 2011;8(4):216–20.PubMedCrossRef
13.
Leverenz JB, Yu CE, Montine TJ, Steinbart E, Bekris LM, Zabetian C, et al. A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain. 2007;130(5):1360–74.PubMedCrossRef
14.
Yongdui C, Li S, Su L, Sheng J, Wen L, Chen G, et al. Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis. J Neurol. 2015;262(4):814–22.CrossRef
15.
Murthy M, Blauwendraat C, Ukbec GS, Ipdgc HJ, et al. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson’s disease on chromosome 7p15.3. Neurogenetics. 2017;18(3):121–33.PubMedPubMedCentralCrossRef
16.
Kumaran R, Cookson MR. Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson’s disease. Hum Mol Genet. 2015;24(R1):R32-44.PubMedPubMedCentralCrossRef
17.
Huang M, Modeste E, Dammer E, Merino P, Taylor G, Duong DM, et al. Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations. Acta Neuropathol Commun. 2020;8(1).
18.
Lui H, Zhang J, Makinson Stefanie R, Cahill Michelle K, Kelley Kevin W, Huang HY, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell. 2016;165(4):921–35.PubMedPubMedCentralCrossRef
19.
Hrabal R, Chen Z, James S, Bennett, Ni F. The hairpin stack fold, a novel protein architecture for a new family of protein growth factors. Nat Struct Mol Biol. 1996;3(9):747–52.CrossRef
20.
Lee WC, Almeida S, Prudencio M, Caulfield TR, Zhang YJ, Tay WM, et al. Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency. Hum Mol Genet. 2013;23(6):1467–78.PubMedPubMedCentralCrossRef
21.
Zhou X, Sullivan PM, Sun L, Hu F. The interaction between progranulin and prosaposin is mediated by granulins and the linker region between saposin B and C. J Neurochem. 2017;143(2):236–43.PubMedPubMedCentralCrossRef
22.
Lee CW, Stankowski JN, Chew J, Cook CN, Lam YW, Almeida S, et al. The lysosomal protein cathepsin L is a progranulin protease. Mol Neurodegeneration. 2017;12(1).
23.
Zhou X, Paushter DH, Feng T, Sun L, Reinheckel T, Hu F. Lysosomal processing of progranulin. Mol Neurodegeneration. 2017;12(1).
24.
Holler CJ, Taylor G, Deng Q, Kukar T. Intracellular proteolysis of progranulin generates stable, lysosomal granulins that are haploinsufficient in patients with frontotemporal dementia caused by GRN mutations. eneuro. 2017;4(4):ENEURO.0100-17.2017.
25.
Suh HS, Choi N, Tarassishin L, Lee SC. Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12). PLoS ONE. 2012;7(4):e35115.PubMedPubMedCentralCrossRef
26.
Guo FJ, Lai Y, Tian Q, Lin E, Kong L, Liu C. Granulin-epithelin precursor (GEP) binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. Arthritis Rheumatism. 2010;62(7):2023.PubMedCrossRef
27.
Kessenbrock K, Fröhlich LF, Sixt M, Lämmermann T, Pfister H, Bateman A, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest. 2008;118(7).
28.
Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al. Conversion of proepithelin to epithelins. Cell. 2002;111(6):867–78.PubMedCrossRef
29.
Du H, Zhou X, Feng T, Hu F. Regulation of lysosomal trafficking of progranulin by sortilin and prosaposin. Brain Commun. 2022;4(1).
30.
Nguyen A, Nguyen T, Basar Cenik YuG, Herz J, Walther TC, et al. Secreted progranulin is a homodimer and is not a component of high density lipoproteins (HDL). J Biol Chem. 2013;288(12):8627–35.PubMedPubMedCentralCrossRef
31.
Galimberti D, Fumagalli G, Fenoglio C, Cioffi S, Arighi A, Serpente M, et al. Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiol Aging. 2018;62(245):e9-12.
32.
Sellami L, Rucheton B, Younes IB, Camuzat A, Saracino D, Rinaldi D, et al. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. Neurobiol Aging. 2020;91:167.CrossRef
33.
Root J, Merino P, Nuckols A, Johnson M, Kukar T. Lysosome dysfunction as a cause of neurodegenerative diseases: lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol Dis. 2021;154: 105360.PubMedPubMedCentralCrossRef
34.
Yao YN, Wang MD, Tang XC, Wu B, Sun HM. Reduced plasma progranulin levels are associated with the severity of Parkinson’s disease. Neurosci Lett. 2020;725: 134873.PubMedCrossRef
35.
Zhou X, Sun L, Bracko O, Choi JW, Jia Y, Nana AL, et al. Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. Nat Commun. 2017;8(1).
36.
Ong C, He Z, Kriazhev L, Shan X, Roger BA. Regulation of progranulin expression in myeloid cells. Am J Physiol Regul Integr Comp Physiol. 2006;291(6):R1602–12.PubMedCrossRef
37.
Kawashima K, Ishiuchi Y, Konnai M, Komatsu S, Sato H, Kawaguchi H, et al. Glucose deprivation regulates the progranulin-sortilin axis in PC12 cells. FEBS Open Bio. 2016;7(2):149–59.PubMedPubMedCentralCrossRef
38.
Menzel L, Kleber L, Friedrich C, Hummel R, Dangel L, Winter J, et al. Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. Glia. 2016;65(2):278–92.PubMedCrossRef
39.
Chen-Plotkin A, Martinez-Lage M, Patrick, Hu WT, Greene R, Wood EM, et al. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol. 2011;68(4):488–98.PubMedPubMedCentralCrossRef
40.
Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmid B, et al. Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem. 2007;283(3):1744–53.PubMedCrossRef
41.
Puoti G, Lerza MC, Ferretti MG, Bugiani O, Tagliavini F, Rossi G. A Mutation in the 5′-UTR of GRN gene associated with frontotemporal lobar degeneration: phenotypic variability and possible pathogenetic mechanisms. J Alzheimer’s Dis. 2014;42(3):939–47.CrossRef
42.
Capell A, Fellerer K, Haass C. Progranulin transcripts with short and long 5′ untranslated regions (UTRs) are differentially expressed via posttranscriptional and translational repression. J Biol Chem. 2014;289(37):25879–89.PubMedPubMedCentralCrossRef
43.
Banzhaf-Strathmann J, Claus R, Mücke O, Rentzsch K, van der Zee J, Engelborghs S, et al. Promoter DNA methylation regulates progranulin expression and is altered in FTLD. Acta Neuropathol Commun. 2013;1(1).
44.
Jiao J, Herl L, Farese RV, Gao FB. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS ONE. 2010;5(5):e10551–61.PubMedPubMedCentralCrossRef
45.
Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln S, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008;17(23):3631–42.PubMedPubMedCentralCrossRef
46.
Wang WX, Wilfred BR, Madathil SK, Tang G, Hu Y, Dimayuga J, et al. miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol. 2010;177(1):334–45.PubMedPubMedCentralCrossRef
47.
Weterman MAJ, Ajubi N, van Dinter IMR, Degen WGJ, van Muijen GNP, Ruiter DJ, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60(1):73–81.PubMedCrossRef
48.
Liguori M, Digifico E, Vacchini A, Avigni R, Colombo F, Borroni EM, et al. The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cell Mol Immunol. 2020;18(3):711–22.PubMedPubMedCentralCrossRef
49.
Rose AAN, Pepin F, Russo C, Khalil JG, Hallett M, Siegel PH. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res. 2007;5(10):1001–14.PubMedCrossRef
50.
51.
52.
Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006;12(7):1970–82.PubMedCrossRef
53.
Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K, Hearing VJ. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. The FASEB J. 2010;24(5):1616–29.PubMedCrossRef
54.
Rose AAN, Annis MG, Dong Z, Pepin F, Hallett M, Park M, et al. ADAM10 releases a soluble form of the GPNMB/osteoactivin extracellular domain with angiogenic properties. PLoS ONE. 2010;5(8):e12093.PubMedPubMedCentralCrossRef
55.
Kramer GJ, Wegdam W, Donker-Koopman WE, Ottenhoff R, Gaspar P, Verhoek M, et al. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS Open Bio. 2016;6(9):902–13.PubMedPubMedCentralCrossRef
56.
Lin J, Zhang P, Huang Y, Wei X, Guo D, Liu J, et al. Elevated circulating Gpnmb levels are associated with hyperthyroidism. Endocr Connect. 2020;9(8):783–92.PubMedPubMedCentralCrossRef
57.
Conway BR, Manoharan D, Manoharan D, Jenks S, Dear JW, McLachlan S, et al. Measuring urinary tubular biomarkers in type 2 diabetes does not add prognostic value beyond established risk factors. Kidney Int. 2012;82(7):812–8.PubMedCrossRef
58.
Murugesan V, Liu J, Yang R, Lin H, Lischuk A, Pastores GM, et al. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease. Blood Cells Mol Dis. 2018;1(68):47–53.CrossRef
59.
Tanaka H, Shimazawa M, Kimura M, Takata M, Tsuruma K, Yamada M, et al. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci Rep. 2012;2(1).
60.
Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of gaucher disease. PLoS ONE. 2015;10(3):e0120194.PubMedPubMedCentralCrossRef
61.
Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-γ and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol. 2007;178(10):6557–66.PubMedCrossRef
62.
Zhou L, Zhuo H, Ouyang H, Liu Y, Yuan F, Sun L, et al. Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. Cell Immunol. 2017;316:53–60.PubMedCrossRef
63.
Shi F, Duan S, Cui J, Yan X, Li H, Wang Y, et al. Induction of matrix metalloproteinase-3 (MMP-3) expression in the microglia by lipopolysaccharide (LPS) via upregulation of glycoprotein nonmetastatic melanoma B (GPNMB) expression. J Mol Neurosci. 2014;54(2):234–42.PubMedCrossRef
64.
Aichholzer F, Klafki HW, Ogorek I, Vogelgsang J, Wiltfang J, Scherbaum N, et al. Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease. Alzheimer’s Res Therapy. 2021;13(1).
65.
Gabriel TL, Tol MJ, Ottenhof R, van Roomen C, Aten J, Claessen N, et al. Lysosomal stress in obese adipose tissue macrophages contributes to MITF-dependent gpnmb induction. Diabetes. 2014;63(10):3310–23.PubMedCrossRef
66.
Gutknecht M, Geiger J, Joas S, Dörfel D, Salih HR, Müller M, et al. The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells. Cell Commun Signaling. 2015;13(1).
67.
Ripoll VM, Meadows NA, Raggatt LJ, Chang MK, Pettit AR, Cassady AI, et al. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene. 2008;413(1–2):32–41.PubMedCrossRef
68.
69.
Jiang SS, Chen CH, Tseng KY, Tsai FY, Wang MJ, Chang IS, et al. Gene expression profiling suggests a pathological role of human bone marrow-derived mesenchymal stem cells in aging-related skeletal diseases. Aging. 2011;3(7):672–84.PubMedPubMedCentralCrossRef
70.
Krasniewski LK, Chakraborty P, Cui CY, Mazan-Mamczarz K, Dunn CA, Piao Y, et al. Single-cell analysis of skeletal muscle macrophages reveals age-associated functional subpopulations. eLife. 2022;11.
71.
Suda M, Shimizu I, Katsuumi G, Yoshida Y, Hayashi Y, Ikegami R, et al. Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nat Aging. 2021;1–10.
72.
Hasan S, Fernandopulle MS, Humble SW, Frankenfield AM, Li H, Prestil R, et al. Multi-modal proteomic characterization of lysosomal function and proteostasis in progranulin-deficient neurons. bioRxiv (Cold Spring Harbor Laboratory). 2023.
73.
Tanaka Y, Suzuki G, Matsuwaki T, Hosokawa M, Serrano G, Beach TG, et al. Progranulin regulates lysosomal function and biogenesis through acidification of lysosomes. Hum Mol Genet. 2017;26(5):ddx011.CrossRef
74.
Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L, et al. Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. Hum Mol Genet. 2017;26(15):2850–63.PubMedPubMedCentralCrossRef
75.
Butler V, Cortopassi WA, Argouarch A, Ivry SL, Craik CS, Jacobson MP, et al. Progranulin stimulates the in vitro maturation of pro-cathepsin D at Acidic pH. J Mol Biol. 2019;431(5):1038–47.PubMedPubMedCentralCrossRef
76.
Valdez C, Wong YC, Schwake M, Bu G, Wszolek ZK, Krainc D. Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Hum Mol Genet. 2017;26(24):4861–72.PubMedPubMedCentralCrossRef
77.
Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F. Regulation of cathepsin D activity by the FTLD protein progranulin. Acta Neuropathol. 2017;134(1):151–3.PubMedPubMedCentralCrossRef
78.
Arrant AE, Roth JR, Boyle NR, Kashyap SN, Hoffmann MQ, Murchison CF, et al. Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations. Acta Neuropathol Commun. 2019;7(1).
79.
Valdez C, Ysselstein D, Young T, Zheng J, Krainc D. Progranulin mutations result in impaired processing of prosaposin and reduced glucocerebrosidase activity. Hum Mol Genet. 2019;29(5):716–26.PubMedCentralCrossRef
80.
Zhou X, Paushter DH, Pagan MD, Kim D, Santos MN, Lieberman RL, et al. Progranulin deficiency leads to reduced glucocerebrosidase activity. PLoS ONE. 2019;14(7):e02123822.CrossRef
81.
Chen Y, Jian J, Hettinghouse A, Zhao X, Setchell KDR, Sun Y, et al. Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease. J Mol Med. 2018;96(12):1359–73.PubMedCrossRef
82.
Boland S, Swarup S, Ambaw YA, Malia PC, Richards RC, Fischer AW, et al. Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis. Nat Commun. 2022;13(1):5924.PubMedPubMedCentralCrossRef
83.
Evers BM, Rodriguez-Navas C, Tesla RJ, Prange-Kiel J, Wasser CR, Yoo KS, et al. Lipidomic and transcriptomic basis of lysosomal dysfunction in progranulin deficiency. Cell Rep. 2017;20(11):2565–74.PubMedPubMedCentralCrossRef
84.
Vandevrede L, Rojas JC, Wang P, Heuer HW, Karydas AM, Ljubenkov PA, et al. Lipid metabolism dysfunction in progranulin mutation carriers: Unbiased metabolomics reveals strong relationship to clinical status in FTLD. Alzheimer’s & Dementia. 2020;16(S5).
85.
86.
Remmel N, Locatelli-Hoops S, Breiden B, Schwarzmann G, Sandhoff K. Saposin B mobilizes lipids from cholesterol-poor and bis(monoacylglycero)phosphate-rich membranes at acidic pH. FEBS J. 2007;274(13):3405–20.PubMedCrossRef
87.
88.
Wilkening G, Linke T, Sandhoff K. Lysosomal degradation on vesicular membrane surfaces. J Biol Chem. 1998;273(46):30271–8.PubMedCrossRef
89.
Chevallier J, Chamoun Z, Jiang G, Prestwich G, Sakai N, Matile S, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J Biol Chem. 2008;283(41):27871–80.PubMedCrossRef
90.
Kirkegaard T, Roth AG, Petersen NHT, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature. 2010;463(7280):549–53.PubMedCrossRef
91.
Matsuo H, Chevallier J, Mayran N, Blanc IL, Ferguson C, Fauré J, et al. Role of LBPA and alix in multivesicular liposome formation and endosome organization. Science. 2004;303(5657):531–4.PubMedCrossRef
92.
Giray E, Mikkolainen H, Gungor B, Ikonen E, Vattulainen I. Concerted regulation of npc2 binding to endosomal/lysosomal membranes by bis(monoacylglycero)phosphate and sphingomyelin. PLoS Compuat Biol. 2017;13(10):e1005831-1.
93.
Hullin-Matsuda F, Luquain-Costaz C, Bouvier J, Delton-Vandenbroucke I. Bis(monoacylglycero)phosphate, a peculiar phospholipid to control the fate of cholesterol: implications in pathology. Prostaglandins Leukotrienes Essential Fatty Acids. 2009;81(5–6):313–24.PubMedCrossRef
94.
Sun S, Zhou J, Li Z, Wu Y, Wang H, Zheng Q, et al. Progranulin promotes hippocampal neurogenesis and alleviates anxiety-like behavior and cognitive impairment in adult mice subjected to cerebral ischemia. CNS Neurosci Ther. 2022;28(5):775–87.PubMedPubMedCentralCrossRef
95.
Beel S, Herdewyn S, Fazal R, De Decker M, Moisse M, Robberecht W, et al. Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. Mol Neurodegeneration. 2018;13(1).
96.
Philips T, De Muynck L, Thu HNT, Weynants B, Vanacker P, Dhondt J, et al. Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol. 2010;69(12):1191–200.PubMedCrossRef
97.
Irwin D, Lippa CF, Rosso A. Progranulin (PGRN) expression in ALS: an immunohistochemical study. J Neurol Sci. 2009;276(1–2):9–13.PubMedCrossRef
98.
Ljubenkov PA, Miller ZA, Mumford P, Zhang J, Allen Isabel Elaine, Mitic LL, et al. Peripheral innate immune activation correlates with disease severity in GRN haploinsufficiency. Front Neurol. 2019;10.
99.
Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2009;207(1):117–28.PubMedCrossRef
100.
Houser MC, Uriarte Huarte O, Wallings R, Keating CE, MacPherson KP, Herrick MK, et al. Progranulin loss results in sex-dependent dysregulation of the peripheral and central immune system. Front Immunol. 2022;22:13.
101.
Suzuki M, Lee HC, Kayasuga Y, Chiba S, Nedachi T, Matsuwaki T, et al. Roles of progranulin in sexual differentiation of the developing brain and adult neurogenesis. J Reprod Dev. 2009;55(4):351–5.PubMedCrossRef
102.
Curtis AF, Masellis M, Hsiung GYR, Moineddin R, Zhang K, Au B, et al. Sex differences in the prevalence of genetic mutations in FTD and ALS: a meta-analysis. Neurology. 2017;89(15):1633–42.PubMedPubMedCentralCrossRef
103.
Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, et al. Sex differences in Alzheimer disease—the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457–69.PubMedCrossRef
104.
Reekes TH, Higginson CI, Ledbetter CR, Sathivadivel N, Zweig RM, Disbrow EA. Sex specific cognitive differences in Parkinson disease. npj Parkinson’s Dis. 2020;6(1).
105.
Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332(6028):478–84.PubMedPubMedCentralCrossRef
106.
Chen X, Chang J, Deng Q, Xu J, Nguyen TA, Martens LH, et al. Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells. J Neurosci. 2013;33(21):9202–13.PubMedPubMedCentralCrossRef
107.
Etemadi N, Webb A, Bankovacki A, Silke J, Nachbur U. Progranulin does not inhibit TNF and lymphotoxin-α signalling through TNF receptor 1. Immunol Cell Biol. 2013;91(10):661–4.PubMedCrossRef
108.
Lang I, Füllsack S, Wajant H. Lack of evidence for a direct interaction of progranulin and tumor necrosis factor receptor-1 and tumor necrosis factor receptor-2 from cellular binding studies. Front Immunol. 2018;23:9.
109.
Hessman CL, Hildebrandt J, Shah A, Brandt S, Bock A, Frye BC, et al. YB-1 interferes with TNFα–TNFR binding and modulates progranulin-mediated inhibition of TNFα signaling. Int J Mol Sci. 2020;21(19):7076–86.PubMedPubMedCentralCrossRef
110.
Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009;10(7):783–9.PubMedPubMedCentralCrossRef
111.
Rauen T, Raffetseder U, Frye B, Djudjaj S, Mühlenberg PJT, Eitner F, et al. YB-1 acts as a ligand for notch-3 receptors and modulates receptor activation. J Biol Chem. 2009;284(39):26928–40.PubMedPubMedCentralCrossRef
112.
Li B, Castano AP, Hudson TE, Nowlin BT, Lin SL, Bonventre JV, et al. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J. 2010;24(12):4767–81.PubMedPubMedCentral
113.
Okita Y, Kimura M, Xie R, Chen C, Shen LTW, Kojima Y, et al. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB. Sci Signaling. 2017;10(474).
114.
Marconi GD, Fonticoli L, Rajan TS, Pierdomenico SD, Trubiani O, Pizzicannella J, et al. Epithelial-mesenchymal transition (EMT): the Type-2 EMT in wound healing, tissue regeneration and organ fibrosis. Cells. 2021;10(7):1587.PubMedPubMedCentralCrossRef
115.
Xie R, Okita Y, Ichikawa Y, Muhammad AF, Tuyen K, PhuongDung ST, et al. Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential. Cancer Sci. 2019;110(7):2237–46.PubMedPubMedCentralCrossRef
116.
117.
Marshall J, Nietupski JB, Park H, Cao J, Bangari DS, Silvescu C, et al. Substrate reduction therapy for sandhoff disease through inhibition of glucosylceramide synthase activity. Mol Ther. 2019;27(8):1495–506.PubMedPubMedCentralCrossRef
118.
Di Liberto G, Egervari K, Kreutzfeldt M, Schürch CM, Hewer E, Wagner I, et al. Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV. Brain. 2022;145(8):2730.PubMedPubMedCentralCrossRef
119.
Ariizumi K, Chung JS, Dougherty I, Cruz P. Function of DC-HIL on T cell activation syndecan-4 mediates the coinhibitory. J Immunol References. 2007;179(9):5778–84.
120.
121.
Ramani V, Chung JS, Ariizumi K, Cruz PD. Soluble DC-HIL/Gpnmb modulates T-lymphocyte extravasation to inflamed skin. J Investig Dermatol. 2022;142(5):1372–80.PubMedCrossRef
122.
Prabata A, Ikeda K, Rahardini EP, Hirata KI, Emoto N. GPNMB plays a protective role against obesity-related metabolic disorders by reducing macrophage inflammatory capacity. J Biol Chem. 2021;297(5): 101232.PubMedPubMedCentralCrossRef
123.
Neal ML, Boyle AM, Budge KM, Safadi FF, Richardson JR. The glycoprotein GPNMB attenuates astrocyte inflammatory responses through the CD44 receptor. J Neuroinflammation. 2018;15(1).
124.
Ono Y, Kazuhiro Tsuruma, Takata M, Masamitsu Shimazawa, Hara H. Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na+/K+-ATPase. Sci Rep. 2016;6(1).
125.
Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A, et al. Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Sci Transl Med. 2017;9(385).
126.
Mackenzie IRA. The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol. 2007;114(1):49–54.PubMedCrossRef
127.
Rademakers R, Baker M, Gass J, Adamson J, Huey ED, Momeni P, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. Lancet Neurol. 2007;6(10):857–68.PubMedCrossRef
128.
Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, et al. Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. J Exp Med. 2017;214(9):2611–28.PubMedPubMedCentralCrossRef
129.
Ward ME, Taubes A, Chen R, Miller BL, Sephton CF, Gelfand JM, et al. Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. J Exp Med. 2014;211(10):1937–45.PubMedPubMedCentralCrossRef
130.
Marques ARA, Gabriel TL, Aten J, van Roomen CPAA, Ottenhoff R, Claessen N, et al. Gpnmb is a potential marker for the visceral pathology in niemann-pick type C disease. PLoS ONE. 2016;11(1):e0147208.PubMedPubMedCentralCrossRef
131.
Platt FM, d’Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1).
132.
La Cognata V, Guarnaccia M, Polizzi A, Ruggieri M, Cavallaro S. Highlights on genomics applications for lysosomal storage diseases. Cells. 2020;9(8).
133.
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–9.PubMedCrossRef
134.
Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920–4.PubMedCrossRef
135.
Sassi C, Capozzo R, Hammer M, Zecca C, Federoff M, Cornelis Blauwendraat, et al. Exploring dementia and neuronal ceroid lipofuscinosis genes in 100 FTD-like patients from 6 towns and rural villages on the Adriatic Sea cost of Apulia. Sci Rep. 2021;11(1).
136.
Smith Katherine R, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M, et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Human Genet. 2012;90(6):1102–7.CrossRef
137.
Benussi L, Binetti G, Sina E, Gigola L, Meitinger T, Ghidoni R. A novel deletion in progranulin gene is associated with FTDP-17 and CBS. Neuobiol Aging. 2008;29(3):427–35.CrossRef
138.
Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain J Neurol. 2008;131(Pt 3):732–46.CrossRef
139.
Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, Steinbart E, et al. The spectrum of mutations in progranulin. Arch Neurol. 2010;67(2).
140.
Almeida MR, Macário MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I. Portuguese family with the co-occurrence of frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis phenotypes due to progranulin gene mutation. Neurobiol Aging. 2016;41(200):e1-5.
141.
Bossolasco P, Cimini S, Maderna E, Bardelli D, Canafoglia L, Cavallaro T, et al. GRN-/- iPSC-derived cortical neurons recapitulate the pathological findings of both frontotemporal lobar degeneration and neuronal ceroidolipofuscinosis. Neurobiol Dis. 2022;175:105891.PubMedCrossRef
142.
Siintola E. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain. 2006;129(6):1438–45.PubMedCrossRef
143.
Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Brück W, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Human Genet. 2006;78(6):988–98.CrossRef
144.
Kyttälä A, Lahtinen U, Braulke T, Hofmann SL. Functional biology of the neuronal ceroid lipofuscinoses (NCL) proteins. Biochimica et Biophysica Acta (BBA) Mol Basis Dis. 2006;1762(10):920–33.CrossRef
145.
Ahmed Z, Sheng H, Xu Y, Lin WL, Innes AE, Gass J, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311–24.PubMedPubMedCentralCrossRef
146.
Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis. 2012;45(1):395–408.PubMedCrossRef
147.
Petkau TL, Hill A, Leavitt BR. Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. Neuroscience. 2016;315:175–95.PubMedCrossRef
148.
Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, et al. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. FASEB J. 2010;24(12):4639–47.PubMedPubMedCentral
149.
Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, et al. Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J Pathol. 2012;228(1):67–76.PubMedCrossRef
150.
Martens LH, Zhang J, Barmada SJ, Zhou P, Kamiya S, Sun B, et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J Clin Investig. 2012;122(11):3955–9.PubMedPubMedCentralCrossRef
151.
Arrant AE, Filiano AJ, Warmus BA, Hall AM, Roberson ED. Progranulin haploinsufficiency causes biphasic social dominance abnormalities in the tube test. Genes Brain Behav. 2016;15(6):588–603.PubMedCrossRef
152.
Filiano AJ, Martens LH, Young AJ, Warmus BA, Zhou P, Diaz-Ramirez G, et al. Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J Neurosci. 2013;33(12):5352–61.PubMedPubMedCentralCrossRef
153.
Nguyen AD, Nguyen TA, Zhang J, Devireddy S, Zhou P, Karydas AM, et al. Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. Proc Natl Acad Sci. 2018;115(12).
154.
Frew J, Nygaard HB. Neuropathological and behavioral characterization of aged Grn R493X progranulin-deficient frontotemporal dementia knockin mice. Acta Neuropathol Commun. 2021;9(1).
155.
Klein Z, Takahashi H, Ma M, Stagi M, Zhou M, Lam T, et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia-related phenotypes in progranulin-deficient mice. Neuron. 2017;95(2):281-296.e6.PubMedPubMedCentralCrossRef
156.
Petkau TL, Blanco J, Leavitt BR. Conditional loss of progranulin in neurons is not sufficient to cause neuronal ceroid lipofuscinosis-like neuropathology in mice. Neurobiol Dis. 2017;106:14–22.PubMedCrossRef
157.
Arrant AE, Filiano AJ, Patel AR, Hoffmann MQ, Boyle NR, Kashyap S, et al. Reduction of microglial progranulin does not exacerbate pathology or behavioral deficits in neuronal progranulin-insufficient mice. Neurobiol Dis. 2019;1(124):152–62.CrossRef
158.
Petkau TL, Life B, Lu G, Yang JJ, Fornes O, Wasserman WW, et al. Human progranulin-expressing mice as a novel tool for the development of progranulin-modulating therapeutics. Neurobiol Dis. 2021;1(153):105314–24.CrossRef
159.
Daniel RL, Daniels E, He Z, Bateman A. Progranulin (acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is expressed in the placenta, epidermis, microvasculature, and brain during murine development. Dev Dyn. 2003;227(4):593–9.PubMedCrossRef
160.
Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem. 2000;48(7):999–1009.PubMedCrossRef
161.
Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation. 2007;4(1).
162.
Nelvagal HR, Lange J, Takahashi K, Tarczyluk-Wells MA, Cooper JD. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochimica et Biophysica Acta (BBA) Mol Basis Dis. 2020;1866(9):165570.CrossRef
163.
Rodriguez-Gil JL, Baxter LL, Watkins-Chow DE, Johnson NL, Davidson C, Carlson SR, et al. Transcriptome of HPβCD-treated Niemann-Pick disease type C1 cells highlights GPNMB as a biomarker for therapeutics. Hum Mol Genet. 2021;30(24):2456–68.PubMedPubMedCentralCrossRef
164.
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1).
165.
Sheng J, Su L, Xu Z, Chen G. Progranulin polymorphism rs5848 is associated with increased risk of Alzheimer’s disease. Gene. 2014;542(2):141–5.PubMedCrossRef
166.
Xu HM, Tan L, Wan Y, Tan MS, Zhang W, Zheng ZJ, et al. PGRN is associated with late-onset Alzheimer’s disease: a case-control replication study and meta-analysis. Mol Neurobiol. 2016;54(2):1187–95.PubMedCrossRef
167.
Mateo I, González-Aramburu I, Pozueta A, Vázquez-Higuera JL, Rodríguez-Rodríguez E, Sánchez-Juan P, et al. Reduced serum progranulin level might be associated with Parkinson’s disease risk. Eur J Neurol. 2013;20(12):1571–3.PubMedCrossRef
168.
Coppola G, Karydas A, Rademakers R, Wang Q, Baker M, Hutton M, et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol. 2008;64(1):92–6.PubMedPubMedCentralCrossRef
169.
Cooper YA, Nachun D, Dokuru D, Yang Z, Karydas AM, Serrero G, et al. Progranulin levels in blood in Alzheimer’s disease and mild cognitive impairment. Ann Clin Transl Neurol. 2018;5(5):616–29.PubMedPubMedCentralCrossRef
170.
Batzu L, Westman E, Pereira JB. Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer’s disease. Neurobiol Aging. 2019;88.
171.
Morenas-Rodríguez E, Cervera-Carles L, Vilaplana E, Alcolea D, Carmona-Iragui M, Dols-Icardo O, et al. Progranulin protein levels in cerebrospinal fluid in primary neurodegenerative dementias. J Alzheimer’s Dis. 2016;50(2):539–46.CrossRef
172.
McGrowder DA, Miller F, Vaz K, Nwokocha C, Wilson-Clarke C, Anderson-Cross M, et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease: current evidence and future perspectives. Brain Sci. 2021;11(2):215.PubMedPubMedCentralCrossRef
173.
Xu W, Tan CC, Cao XP, Tan L. Neuroinflammation modulates the association of PGRN with cerebral amyloid-β burden. Neurobiol Aging. 2021;103:52–9.PubMedCrossRef
174.
Suárez‐Calvet M, Capell A, Araque Caballero MÁ, Morenas‐Rodríguez E, Fellerer K, Franzmeier N, et al. CSF progranulin increases in the course of Alzheimer’s disease and is associated with sTREM2, neurodegeneration and cognitive decline. EMBO Mol Med. 2018;10(12).
175.
Mao Q, Zheng X, Gefen T, Rogalski E, Spencer C, Rademakers R, et al. FTLD-TDP with and without GRN mutations cause different patterns of CA1 pathology. J Neuropathol Exp Neurol. 2019;78(9):844–53.PubMedPubMedCentralCrossRef
176.
Mendsaikhan A, Tooyama I, Walker DG. Microglial progranulin: involvement in Alzheimer’s disease and neurodegenerative diseases. Cells. 2019;8(3):230.PubMedPubMedCentralCrossRef
177.
Mendsaikhan A, Tooyama I, Serrano GE, Beach TG, Walker DG. Loss of lysosomal proteins progranulin and prosaposin associated with increased neurofibrillary tangle development in Alzheimer disease. J Neuropathol Exp Neurol. 2021;80(8):741–53.PubMedPubMedCentralCrossRef
178.
Pereson S, Wils H, Kleinberger G, McGowan E, Vandewoestyne M, Van Broeck B, et al. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. J Pathol. 2009;219(2):173–81.PubMedCrossRef
179.
Minami SS, Min SW, Krabbe G, Wang C, Zhou Y, Asgarov R, et al. Progranulin protects against amyloid β deposition and toxicity in Alzheimer’s disease mouse models. Nat Med. 2014;20(10):1157–64.PubMedPubMedCentralCrossRef
180.
Du H, Ying Wong M, Zhang T, Nunez Santos M, Hsu C, Zhang J, et al. A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses. Life Sci Alliance. 2021;4(7):e202000874–84.PubMedPubMedCentralCrossRef
181.
Guan Z, Chen Z, Fu S, Dai L, Shen Y. Progranulin administration attenuates β-amyloid deposition in the hippocampus of 5xFAD mice through modulating BACE1 expression and microglial phagocytosis. Front Cell Neurosci. 2020;18:14.
182.
Kampen V, Kay DG. Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer’s disease. PLoS ONE. 2017;12(8):e0182896-e182906.PubMedPubMedCentralCrossRef
183.
Hosokawa M, Arai T, Masuda-Suzukake M, Kondo H, Matsuwaki T, Nishihara M, et al. Progranulin reduction is associated with increased tau phosphorylation in P301L tau transgenic mice. J Neuropathol Exp Neurol. 2015;74(2):158–65.PubMedCrossRef
184.
Takahashi H, Klein ZA, Bhagat SM, Kaufman AC, Kostylev MA, Ikezu T, et al. Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network. Acta Neuropathol. 2017;133(5):785–807.PubMedPubMedCentralCrossRef
185.
Satoh J, Kino Y, Yanaizu M, Ishida T, Saito Y. Microglia express GPNMB in the brains of Alzheimer’s disease and Nasu-Hakola disease. Intractable Rare Dis Res. 2019;8(2):120–8.PubMedPubMedCentralCrossRef
186.
Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, et al. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6(1).
187.
Zhu Z, Liu Y, Li X, Zhang L, Liu H, Cui Y, et al. GPNMB mitigates Alzheimer’s disease and enhances autophagy via suppressing the mTOR signal. Neurosci Lett. 2022;767: 136300.PubMedCrossRef
188.
Wang H, Dey KK, Chen PC, Li Y, Niu M, Cho JH, et al. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease. Mol Neurodegeneration. 2020;15(1).
189.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3(3):17013.PubMedCrossRef
190.
Van Kampen JM, Baranowski D, Kay DG. Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson’s disease. PLoS ONE. 2014;9(5):e97032.PubMedPubMedCentralCrossRef
191.
Sarkar S, Dammer EB, Malovic E, Olsen AL, Ali Raza S, Gao T, et al. Molecular signatures of neuroinflammation induced by αsynuclein aggregates in microglial cells. Front Immunol. 2020;31:11.
192.
Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett P. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;1(120):1–11.CrossRef
193.
Smajić S, Prada-Medina CA, Landoulsi Z, Ghelfi J, Delcambre S, Dietrich C, et al. Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain J Neurol. 2022;145(3):964–78.CrossRef
194.
Diaz-Ortiz ME, Seo Y, Posavi M, Carceles Cordon M, Clark E, Jain N, et al. GPNMB confers risk for Parkinson’s disease through interaction with α-synuclein. Science. 2022;377(6608).
195.
Brendza RP, Lin H, Stark KL, Foreman O, Tao J, Pierce AA, et al. Genetic ablation of Gpnmb does not alter synuclein-related pathology. Neurobiol Dis. 2021;1(159):105494–504.CrossRef
196.
Budge KM, Neal ML, Richardson JR, Safadi FF. Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration. Mol Neurobiol. 2020;57(7):2920–33.PubMedCrossRef
197.
Ma Y, Matsuwaki T, Keitaro Yamanouchi K, Nishihara M. Progranulin protects hippocampal neurogenesis via suppression of neuroinflammatory responses under acute immune stress. Mol Neurobiol. 2016;54(5):3717–28.PubMedCrossRef
198.
Takahashi K, Nakamura S, Otsu W, Shimazawa M, Hara H. Progranulin deficiency in Iba-1+ myeloid cells exacerbates choroidal neovascularization by perturbation of lysosomal function and abnormal inflammation. J Neuroinflammation. 2021;18(1).
199.
Götzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, et al. Common pathobiochemical hallmarks of progranulin-associated frontotemporal lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol. 2014.
200.
Hafler BP, Klein ZA, Zhou Z, Strittmatter SM. Progressive retinal degeneration and accumulation of autofluorescent lipopigments in Progranulin deficient mice. Brain Res. 2014;1(1588):168–74.CrossRef
201.
Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M. Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice. Acta Neuropathol Commun. 2014;2(1).
202.
Götzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S, et al. Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice. Mol Neurodegeneration. 2018;13(1).
203.
Wang C, Zhang L, Ndong JDLC, Hettinghouse A, Sun G, Chen C, et al. Progranulin deficiency exacerbates spinal cord injury by promoting neuroinflammation and cell apoptosis in mice. J Neuroinflammation. 2019;16(1).
204.
Yu Y, Xu X, Liu L, Mao S, Feng T, Lu Y, et al. Progranulin deficiency leads to severe inflammation, lung injury and cell death in a mouse model of endotoxic shock. J Cell Mol Med. 2016;20(3):506–17.PubMedPubMedCentralCrossRef
205.
Zhang T, Feng T, Wu K, Guo J, Nana AL, Yang G, et al. Progranulin deficiency results in sex-dependent alterations in microglia in response to demyelination. Acta Neuropathol. 2023;146(1):97–119.PubMedPubMedCentralCrossRef
206.
Du H, Cha Y, Nana AL, Seeley WW, Smolka MB, Hu F. Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation. bioRxiv (Cold Spring Harbor Laboratory). 2023;
207.
Logan T, Simon MJ, Rana A, Cherf GM, Srivastava A, Davis SS, et al. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell. 2021;184(18):4651-4668.e25.PubMedPubMedCentralCrossRef
208.
Smith DM, Aggarwal G, Niehoff ML, Jones SA, Banerjee S, Farr SA, et al. Biochemical, biomarker, and behavioral characterization of theGrnR493Xmouse model of frontotemporal dementia. bioRxiv (Cold Spring Harbor Laboratory). 2023;
209.
Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, et al. Alteration of behavioural phenotype in mice by targeted disruption of the progranulin gene. Behav Brain Res. 2007;185(2):110–8.PubMedCrossRef
210.
Zhang J, Velmeshev D, Hashimoto K, Huang YH, Hofmann JW, Shi X, et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency. Nature. 2020;588(7838):459–65.PubMedPubMedCentralCrossRef
211.
Arrant AE, Onyilo VC, Unger DE, Roberson ED. Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis. J Neurosci. 2018;38(9):2341–58.PubMedPubMedCentralCrossRef
212.
213.
Root J, Mendsaikhan A, Nandy S, Taylor G, Wang M, Troiano Araujo L, et al. Granulins rescue inflammation, lysosome dysfunction, and neuropathology in a mouse model of progranulin deficiency. bioRxiv (Cold Spring Harbor Laboratory). 2023;
214.
215.
Heckman LD, Burstein SR, Brandes A, Wong LC, Yang Z, Lin H, et al. Preclinical development of PR006, a gene therapy for the treatment of frontotemporal dementia with progranulin mutations. Alzheimer’s & Dementia. 2020;16(S2).
216.
217.
218.
Arechavaleta-Velasco F, Perez-Juarez CE, Gerton GL, Diaz-Cueto L. Progranulin and its biological effects in cancer. Med Oncol. 2017;34(12).
219.
Ventura E, Ducci G, Benot Dominguez R, Ruggiero V, Belfiore A, Sacco E, et al. Progranulin oncogenic network in solid tumors. Cancers. 2023;15(6):1706–16.PubMedPubMedCentralCrossRef
220.
Purrahman D, Mahmoudian-Sani MR, Saki N, Wojdasiewicz P, Kurkowska-Jastrzębska I, Poniatowski ŁA. Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine. 2022;151: 155803.PubMedCrossRef
221.
Yabe K, Yamamoto Y, Takemura M, Hara T, Tsurumi H, Serrero G, et al. Progranulin depletion inhibits proliferation via the transforming growth factor beta/SMAD family member 2 signaling axis in Kasumi-1 cells. Heliyon. 2021;7(1):e05849-e5859.PubMedPubMedCentralCrossRef
222.
Khan SA, Sun Z, Dahlberg SE, Malhotra J, Keresztes R, Ikpeazu C, et al. Efficacy and safety of glembatumumab vedotin in patients with advanced or metastatic squamous cell carcinoma of the lung (PrECOG 0504). JTO Clin Res Rep. 2021;2(5):100166–76.PubMedPubMedCentral
223.
Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children’s Oncology Group. Eur J Cancer. 2019;121:177–83.PubMedPubMedCentralCrossRef
224.
Jin R, Jin Y, Tang Y, Yang H, Zhou X, Lei Z. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway. Oncol Rep. 2018;
Metadata
Title
Progranulin and GPNMB: interactions in endo-lysosome function and inflammation in neurodegenerative disease
Authors
Drew A. Gillett
Rebecca L. Wallings
Oihane Uriarte Huarte
Malú Gámez Tansey
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2023
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-023-02965-w

Other articles of this Issue 1/2023

Journal of Neuroinflammation 1/2023 Go to the issue

Research

Gastrointestinal microbiome of ARDS patients induces neuroinflammation and cognitive impairment in mice

Research

Type I/type III IFN and related factors regulate JEV infection and BBB endothelial integrity

Research

Supraphysiologic doses of 17β-estradiol aggravate depression-like behaviors in ovariectomized mice possibly via regulating microglial responses and brain glycerophospholipid metabolism

Correction

Correction: Motor neuron survival is associated with reduced neuroinflammation and increased autophagy after brachial plexus avulsion injury in aldose reductase-deficient mice

Research

Inducible co-stimulatory molecule (ICOS) alleviates paclitaxel-induced neuropathic pain via an IL-10-mediated mechanism in female mice

Research

Microglial aryl hydrocarbon receptor enhances phagocytic function via SYK and promotes remyelination in the cuprizone mouse model of demyelination